NR4A1 and breast carcinoma: In patients ≥ 70 years with stage I, hormone-receptor (HR) positive and human epidermal growth factor receptor 2 (Her2) negative breast cancer (BC), the routine role of SLNB was questioned, for example, by the CALGB 9343 trial, which showed no disadvantage in oncologic outcomes when surgical staging of the axilla was omitted [9].